CHCT vs FRPH

CHCT exhibits severe valuation misalignment, with a current price of $17.20 trading at a massive premium to its Graham Number ($5.35) and Intrinsic Value ($2.36). While the Piotroski F-Score of 4/9 indicates stable health, the financial fundamentals are undermined by an unsustainable dividend payout ratio of 2356.25% and a trailing P/E of 215.00. Despite a recent 1-year price recovery, the long-term 5-year trend is deeply negative (-52.8%), and the company consistently misses earnings estimates. The high dividend yield is a 'value trap' given that earnings cannot support the current distribution rate.

FRPH exhibits a strong deterministic health profile with a Piotroski F-Score of 8/9 and an exceptional current ratio of 14.77, indicating a fortress balance sheet. However, this financial stability is decoupled from its valuation; the stock trades at a massive premium to its Graham Number ($11.22) and Intrinsic Value ($1.75), with a P/E ratio of 90.88. Severe earnings contraction (-57.10% YoY) combined with bearish insider selling and a negative long-term price trend suggests the current valuation is unsustainable.